Heart failure etiology |
|
|
|
Chagas, n (%) |
16 (72.7%) |
13 (18.3%) |
<0.001 |
Idiopathic, n (%) |
1 (4.5%) |
27 (38.0%) |
0.003 |
Ischemic, n (%) |
1 (4.5%) |
14 (19.7%) |
0.109 |
Age, years (±SD) |
62.4 (±13.8) |
56.6 (±11.4) |
0.080 |
Male gender, n (%) |
15 (68.2%) |
36 (50.7%) |
0.220 |
LVEF, mean (±SD) |
22.3 (±7.1) |
24.4 (±7.6) |
0.249 |
NYHA class III or IV, n (%) |
19 (86.4%) |
57 (80.3%) |
0.754 |
Atrial fibrillation, n (%) |
5 (22.7%) |
15 (21.1%) |
1.000 |
QRS > 150ms, n (%) |
21 (95.5%) |
64 (90.1%) |
0.675 |
QRS duration, mean (±SD) |
158.2 (±14.7) |
160.1 (±22.5) |
0.636 |
non-LBBB, n (%) |
1 (4.5%) |
5 (7.0%) |
1.000 |
Myocardial infarction, n (%) |
2 (9.1%) |
10 (14.1%) |
0.725 |
Stroke, n (%) |
3 (13.6%) |
4 (5.6%) |
0.350 |
Hemoglobin, g/dL (±SD) |
11.8 (±3.1) |
12.8 (±1.8) |
0.147 |
Chronic kidney disease, n (%) |
8 (36.4%) |
17 (23.9%) |
0.278 |
Diabetes, n (%) |
7 (31.8%) |
23 (32.4%) |
1.000 |
Medications |
|
|
|
ACEI, ARB or ARNI |
20 (90.9%) |
61 (85.9%) |
0.725 |
Beta-blocker |
21 (95.5%) |
65 (91.5%) |
1.000 |
Spironolactone |
18 (81.8%) |
63 (88.7%) |
0.469 |